Global Trigeminal Neuralgia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Trigeminal Neuralgia treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Allergan Plc, Biogen Inc, Biohaven Pharmaceuticals, Grace Therapeutics LLC, InMed Pharmaceuticals Inc and others.
A Significant contribution to the Trigeminal Neuralgia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Trigeminal Neuralgia pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Trigeminal Neuralgia condition and increased access to investments is encouraging growth of Trigeminal Neuralgia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Trigeminal Neuralgia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Trigeminal Neuralgia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Trigeminal Neuralgia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Trigeminal Neuralgia. Further, orphan drug status, fast track designation, grants awarded and other special status for Trigeminal Neuralgia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Trigeminal Neuralgia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Trigeminal Neuralgia Pipeline candidates-
A Significant contribution to the Trigeminal Neuralgia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Trigeminal Neuralgia pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Trigeminal Neuralgia condition and increased access to investments is encouraging growth of Trigeminal Neuralgia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Trigeminal Neuralgia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Trigeminal Neuralgia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Trigeminal Neuralgia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Trigeminal Neuralgia. Further, orphan drug status, fast track designation, grants awarded and other special status for Trigeminal Neuralgia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Trigeminal Neuralgia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Trigeminal Neuralgia Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Trigeminal Neuralgia drugs
- Late phase: Phase 3 and in-approval Trigeminal Neuralgia drugs
- Company overview
- Snapshot
- Trigeminal Neuralgia therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Trigeminal Neuralgia- Disease Overview
2.2 Trigeminal Neuralgia- Pipeline Snapshot
2.3 Trigeminal Neuralgia- Pipeline Drugs by Phase
2.4 Trigeminal Neuralgia- Pipeline Drugs by Company
2.5 Trigeminal Neuralgia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Allergan Plc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.2 Biogen Inc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.3 Biohaven Pharmaceuticals Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.4 Grace Therapeutics LLC Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.5 InMed Pharmaceuticals Inc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.6 Merz Pharma GmbH & Co. KgaA Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.7 OliPass Corporation Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.8 PixarBio Corporation Trigeminal Neuralgia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Trigeminal Neuralgia- Phase 1 Drug Details
4.2 Trigeminal Neuralgia- Phase 1 Drug Overview
4.3 Trigeminal Neuralgia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Trigeminal Neuralgia- Phase 2 Drug Details
5.2 Trigeminal Neuralgia- Phase 2 Drug Overview
5.3 Trigeminal Neuralgia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Trigeminal Neuralgia- Phase 3 Drug Details
6.2 Trigeminal Neuralgia- Phase 3 Drug Overview
6.3 Trigeminal Neuralgia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Trigeminal Neuralgia- Pre-clinical Phase Drug Details
7.2 Trigeminal Neuralgia- Pre-clinical Phase Drug Overview
7.3 Trigeminal Neuralgia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Trigeminal Neuralgia- Disease Overview
2.2 Trigeminal Neuralgia- Pipeline Snapshot
2.3 Trigeminal Neuralgia- Pipeline Drugs by Phase
2.4 Trigeminal Neuralgia- Pipeline Drugs by Company
2.5 Trigeminal Neuralgia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Allergan Plc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.2 Biogen Inc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.3 Biohaven Pharmaceuticals Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.4 Grace Therapeutics LLC Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.5 InMed Pharmaceuticals Inc Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.6 Merz Pharma GmbH & Co. KgaA Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.7 OliPass Corporation Trigeminal Neuralgia Drug Pipeline, H2- 2019
3.8 PixarBio Corporation Trigeminal Neuralgia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Trigeminal Neuralgia- Phase 1 Drug Details
4.2 Trigeminal Neuralgia- Phase 1 Drug Overview
4.3 Trigeminal Neuralgia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Trigeminal Neuralgia- Phase 2 Drug Details
5.2 Trigeminal Neuralgia- Phase 2 Drug Overview
5.3 Trigeminal Neuralgia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Trigeminal Neuralgia- Phase 3 Drug Details
6.2 Trigeminal Neuralgia- Phase 3 Drug Overview
6.3 Trigeminal Neuralgia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Trigeminal Neuralgia- Pre-clinical Phase Drug Details
7.2 Trigeminal Neuralgia- Pre-clinical Phase Drug Overview
7.3 Trigeminal Neuralgia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
